Dynavax Technologies Co. (DVAX:NSD) is expected to report earnings of ($0.11) per share for Q1 2024, according to a recent research note by William Blair analyst M. Phipps. The consensus estimate for the biopharmaceutical company’s full-year earnings is ($0.37) per share. William Blair also provided estimates for Dynavax stock Q2 2024 earnings at ($0.12) EPS, Q3 2024 earnings at ($0.10) EPS, Q4 2024 earnings at ($0.12) EPS, and FY2026 earnings at $0.22 EPS.
Synavax Stock-Analyst Ratings:
Recently, several brokerages have weighed in on DVAX stock, with JMP Securities raising its price objective to $25.00 and giving the company a “market outperform” rating, while HC Wainwright lowered its price target to $27.00 and issued a “buy” rating. The consensus rating for Dynavax stock on Stock Target Advisor is “Strong Buy” with an average price target of $23.75.
Dynavax Stock Price Analysis:
Despite the mixed analyst outlook, DVAX’s stock price has seen little movement. It opened at $10.36 on Monday, with a 50-day moving average of $11.10 and a 200-day moving average of $11.55.
DVAX has a market cap of $1.32 billion, a price-to-earnings ratio of 5.26, and a beta of 1.42. The company has a quick ratio of 3.40, a current ratio of 3.82, and a debt-to-equity ratio of 0.44.
Dynavax Stock-Insider Transactions:
In December 2021, DVAX’s Director Andrew A. F. Hack sold 1,500,000 shares of the company’s stock at an average price of $11.60, bringing the total value of the sale to $17,400,000.00. Corporate insiders now own 9.31% of Dynavax stock.
Hedge Funds & Institutional Holdings:
Several large investors have recently increased or decreased their stakes in DVAX, with State Street Corp and Vanguard Group Inc. now owning 10,274,230 and 8,165,641 shares, respectively. Chicago Capital LLC and Blair William & Co. IL also increased their holdings in DVAX, while Geode Capital Management LLC raised their holdings by 3.7%.
Overall, DVAX’s future remains uncertain, with analysts divided on the company’s outlook. Despite the recent insider selling and mixed analyst ratings, Dynavax stock has seen little movement in recent months.
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for the prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; an agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp.
The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.